XORTX Therapeutics (XRTX) announces that, further to its news release of March 26, the implementation of its share consolidation on the basis of one new common share for every five old common shares has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange and will occur on April 6.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Shareholders Approve Governance Measures and Share Consolidation at Annual Meeting
- XORTX Delays Effective Date of One-for-Five Share Consolidation
- XORTX Consolidates Shares in Bid to Maintain Nasdaq Listing
- XORTX Shareholders Approve Reverse Split to Preserve Nasdaq Listing
- XORTX Ties Board Shake-Up to Financing Ahead of March 24 Shareholder Vote